Smac Mimetic LCL161

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

Conditions

Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis

Trial Timeline

Dec 18, 2014 → May 19, 2022

NCT ID

NCT02098161

About Smac Mimetic LCL161

Smac Mimetic LCL161 is a phase 2 stage product being developed by Novartis for Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT02098161. Target conditions include Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis.

What happened to similar drugs?

2 of 17 similar drugs in Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase were approved

Approved (2) Terminated (1) Active (15)

🔄Sapablursen + PlaceboOno PharmaceuticalPhase 3

🔄Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3

🔄ruxolitinib tabletsNovartisPhase 3

🔄RuxolitinibNovartisPhase 3

✅HydroxyureaNovartisApproved

🔄Best Available Therapy + RuxolitinibNovartisPhase 3

🔄PEGASYS + Hydroxyurea + AspirinRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02098161	Phase 2	Completed	Dec 18, 2014	May 19, 2022	Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

Competing Products

20 competing products in Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase

See all competitors

Product	Company	Stage	Hype Score
Sapablursen + Placebo	Ono Pharmaceutical	Phase 3	47
Ruxolitinib + Abemaciclib	Eli Lilly	Phase 1	36
Bomedemstat	Merck	Phase 2	35
Ruxolitinib + Hydroxycarbamide + Interferon-Alpha	Novartis	Phase 3	47
ruxolitinib tablets	Novartis	Phase 3	40
Ruxolitinib	Novartis	Pre-clinical	26
Ruxolitinib	Novartis	Phase 3	40
Ruxolitinib + BAT	Novartis	Phase 2	39
Hydroxyurea	Novartis	Approved	35
Best Available Therapy + Ruxolitinib	Novartis	Phase 3	40
PEGASYS + Aspirin	Roche	Phase 2	35
RG7388 + Pegasys	Roche	Phase 1	29
Idasanutlin	Roche	Phase 2	27
PEGASYS + Hydroxyurea + Aspirin	Roche	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Phase 2	39
Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen	PharmaEssentia	Phase 3	40
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)	PharmaEssentia	Phase 3	40
Ropeginterferon alfa-2b	PharmaEssentia	Approved	50
P1101 + Low-dose aspirin	PharmaEssentia	Phase 2	35
P1101 (Ropeginterferon alfa-2b)	PharmaEssentia	Phase 3	47